PROFILPELAJAR.COM

Dimethyltryptamine/harmine

Not to be confused with Dimethyltryptamine/β-carbolines.
Dimethyltryptamine/harmine
Dimethyltryptamine
Harmine
Combination of
DimethyltryptamineSerotonergic psychedelic; Serotonin receptor agonist
HarmineReversible inhibitor of monoamine oxidase A
Clinical data
Other namesDMT/harmine; Harmine/dimethyltryptamine; Harmine/DMT; Dimethyltryptamine/telepathine; DMT/telepathine; Telepathine/dimethyltryptamine; telepathine/DMT; RE01
Routes of
administration		Unspecified[1]

Dimethyltryptamine/harmine (developmental code name RE01 or RE-01) is a combination of dimethyltryptamine (DMT), a tryptamine serotonin receptor agonist and serotonergic psychedelic, and harmine, a β-carboline reversible inhibitor of monoamine oxidase A (RIMA), which is under development for the treatment of mood disorders.[1][2][3]

It is a form of pharmahuasca (pharmaceutical ayahuasca), in which DMT is combined with a synthetically produced monoamine oxidase inhibitor (MAOI) as opposed to a plant-derived form such as Banisteriopsis caapi as in ayahuasca.[4] Harmine, acting as a RIMA, inhibits the metabolism of DMT, in turn greatly potentiating DMT and allowing it to become orally active.[5][6][7]

The combination is being developed by Reconnect Labs.[1][2][3] As of August 2023, it is in phase 1 clinical trials.[1][2][3]

See also

References

  1. ^ a b c d "Dimethyltryptamin/harmine". AdisInsight. 28 August 2023. Retrieved 28 February 2025.
  2. ^ a b c "Delving into the Latest Updates on Dimethyltryptamine/Telepathine with Synapse". Synapse. 26 January 2025. Retrieved 28 February 2025.
  3. ^ a b c "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 28 February 2025.
  4. ^ Brierley DI, Davidson C (December 2012). "Developments in harmine pharmacology--implications for ayahuasca use and drug-dependence treatment". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 39 (2): 263–272. doi:10.1016/j.pnpbp.2012.06.001. PMID 22691716.
  5. ^ Dos Santos RG, Hallak JE (November 2024). "Ayahuasca: pharmacology, safety, and therapeutic effects". CNS Spectrums. 30 (1) e2: 1–9. doi:10.1017/S109285292400213X. PMID 39564645.
  6. ^ Egger K, Aicher HD, Cumming P, Scheidegger M (September 2024). "Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors". Cellular and Molecular Life Sciences. 81 (1) 395. doi:10.1007/s00018-024-05353-6. PMC 11387584. PMID 39254764.
  7. ^ Berlowitz I, Egger K, Cumming P (2022). "Monoamine Oxidase Inhibition by Plant-Derived β-Carbolines; Implications for the Psychopharmacology of Tobacco and Ayahuasca". Frontiers in Pharmacology. 13 886408. doi:10.3389/fphar.2022.886408. PMC 9121195. PMID 35600851.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.